Linghua Wang, M.D., Ph.D.
Department of Genomic Medicine, Division of Cancer Medicine
About Dr. Wang
Dr. Wang is a tenured Associate Professor in the Department of Genomic Medicine, where she leads the Computational Biology Laboratory. She has significant expertise in computational biology, cancer genomics, and immuno-informatics. Her group specializes in deep profiling of the tumor ecosystem, including its cellular and molecular heterogeneity, phenotypic plasticity, dynamics, and interactions between cancer cells and cells of the tumor microenvironment (TME) during tumor initiation, progression, metastasis, response, and resistance to therapy. They leverage cutting-edge single-cell and spatial multi-omics technologies and cellular imaging, combined with the development and innovative use of state-of-the-art bioinformatics tools and computational frameworks for novel discovery.
Dr. Wang’s Lab has several key areas of focus: 1) Transition from premalignant lesions to invasive cancer: The lab comprehensively characterizes the cellular and molecular trajectories of tumor development and progression, aiming to develop classifiers and risk prediction models for better patient stratification and to identify potential targets for developing effective interception strategies. 2) Evolution of metastasis from a localized tumor: The lab explores the cellular and molecular underpinnings of metastases, seeking to understand the co-evolution of cancer cells with the TME, and the adaptive interactions between cancer cells and various immune and stromal cells within both primary and metastatic microenvironments. 3) Dynamic response to anti-cancer therapies and the development of therapeutic resistance: The lab aims to pinpoint both intrinsic factors in cancer cells and the microenvironmental factors that determine tumor responses to anti-cancer therapies, identify robust biomarkers and develop models to predict patient response prior to treatment, and discover new targets for developing effective combination therapies.
Dr. Wang has established an impactful research portfolio, leveraging a collaborative, team-based approach to tackling cancer. She is the Principal Investigator (PI) for an R01 grant and MPI for a U01 grant, both sponsored by the National Institutes of Health/National Cancer Institute (NIH/NCI). She is the PI/MPI for two Individual Investigator Research Awards (IIRA) funded by the Cancer Prevention and Research Institute of Texas (CPRIT). Dr. Wang has been honored with the Emil Frei, III Award for Excellence in Translational Research, the David M. Livingston Collaboration Award, and the Sabin Fellow Award. She currently serves as the site Lead of Data Science for the Pancreatic and Ovarian Cancer Programs supported by Break Through Cancer (BTC), Co-Lead of the BTC Data Science TeamLab, and Lead of the Data Analysis and Visualization Unit for an NIH/NCI U24 grant. She also co-leads the High-Risk Multiple Myeloma Moon Shot Program at MD Anderson Cancer Center and is the Co-Director of the Biostatistics and Bioinformatics Core for the MD Anderson GI SPORE Program.
Dr. Wang has a distinguished record of research productivity, having authored over 120 publications, including around 40 published as the first/co-first, senior and/or corresponding author in high-impact journals, such as Nature (2014, 2020, 2024), Nature Medicine (2020, 2021, 2023), Cancer Cell (2022, 2023a, 2023b), Cancer Discovery (2021, 2022a, 2022b), Nature Genetics (2015), Gastroenterology (2024), Nature Communications (n=5), Science Translational Medicine (2019), Lancet Oncology (2022), Neuro-Oncology (2024), Gut (2019, 2020), Clinical Cancer Research (2019), Cell Systems (2023a, 2023b), Blood Cancer Discovery (2022), and Leukemia (2014a, 2014b), among others. Dr. Wang is a recognized investigator in her field with a proven track record. She has been invited to serve on multiple grant review panels for the NIH/NCI, and as Session Chair or Co-Chair for major annual meetings such as the AACR Annual Meeting, SITC Annual Meeting, and the ENAR Spring Meeting. She also serves as a Scientific Editor for the journal ‘Cancer Discovery’. Dr. Wang actively collaborates with experts both nationally and internationally, harnessing the power of data science to better understand, detect, and treat cancer.
In the News
Study unravels the earliest cellular genesis of lung adenocarcinoma
New single-cell study provides novel insights into gastric cancer
Study brings new understanding of multiple myeloma evolution
Pan-cancer T cell atlas reveals new details of tumor microenvironment
Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses
Spatial omics offer a deeper look at tertiary lymphoid structures in cancer
From a small village in China to MD Anderson: Genomic medicine researcher looks to the future of big data in cancer care
2019 Andrew Sabin Family Fellows share passion for Making Cancer History
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Regular Member, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX
Research Interests
Single-cell and spatial multi-omics | Spatial analysis of cellular neighborhood | Tumor heterogeneity and cancer cell plasticity | Tumor evolution | Tumor microenvironment | Tumor-immune interactions | Tertiary lymphoid structures
Education & Training
Degree-Granting Education
2011 | The University of Tokyo Graduate School of Engineering, Tokyo, JPN, PHD, Cancer Genomics |
2006 | Sun Yat-Sen University School of Medicine, Guangzhou, CHN, MS, Ophthalmology |
2003 | Shandong First Medical University (Shandong Academy of Medical Sciences), Taian, CHN, MD, Clinical Medicine |
Postgraduate Training
2012-2014 | Postdoctoral Fellow, Cancer Genomics, Baylor College of Medicine, Houston, TX |
2007-2008 | Research Fellowship, Cancer Genetics, Nihon University School of Medicine, Tokyo |
Experience & Service
Academic Appointments
Assistant Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2022
Assistant Professor, Baylor College of Medicine, Houston, TX, 2015 - 2017
Instructor, Baylor College of Medicine, Houston, TX, 2014 - 2015
Other Appointments/Responsibilities
MD Anderson Core Facility Oversight Board, University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Member, Allison Institute Advisory Council (AIAC), The James P. Allison Institute (JPAI), University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Member, CCSG Program, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Member, Cancer Biology and Metastasis Program, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Honors & Awards
2023 | David M. Livingston Collaboration Award, Break Through Cancer (BTC) |
2023 | Keynote Speaker (AI, Machine Learning, Systems & Spatial Biology in Oncology Conference 2023), Mayo Clinic |
2023 | Invited Speaker (Major Symposium), AACR Annual Meeting |
2023 | Invited Speaker, Frontiers in Single Cell Genomics, Cold Spring Harbor Asia (CSHA) |
2023 | Session Chair (Statistical methods for omics data), ENAR 2023 Spring Meeting |
2023 | Invited Speaker, ENAR 2023 Spring Meeting |
2022 | Excellence in Science (Team Co-Lead), MDACC |
2022 | Session co-Chair (Bioinformatics and Computational Biology), AACR Annual Meeting 2022 |
2022 | Session co-Chair (Big Data & Bioinformatics), SITC Annual Meeting 2022 |
2022 | Invited Speaker, Frontiers in Cancer Immunotherapy 2022, New York Academy of Sciences (NYAS) |
2022 | Invited Speaker, Single-Cell Cancer Biology Gordon Research Conference 2022 |
2022 | Invited Speaker, SITC Annual Meeting 2022 |
2022 | Emil Frei, III Award for Excellence in Translational Research, MDACC |
2021 | Excellence in Science (Team Lead), MDACC |
2021 | Excellence in Science (Team Co-Lead), MDACC |
2021 | Women in Science, Women’s History Month, MDACC |
2019 | Sabin Fellow Award, Sabin Family Foundation |
2017 | Invited Speaker, AACR Annual Meeting 2017, AACR |
2016 | Invited Speaker, Human Genome Meeting, Human Genome Organization (HUGO) |
2011 | Invited Speaker, The Biology of Genomes 2011, Cold Spring Harbor Laboratory (CSHL) |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med. e-Pub 2024. PMID: 39151421.
- Gupta P, Dang M, Oberai S, Migliozzi S, Trivedi R, Kumar G, Peshoff M, Milam N, Ahmed A, Bojja K, Tran TM, Gumin J, Kamiya-Matsuoka C, Huse J, Cox K, Li J, Shehwana H, Sheth SA, Saxon R, Baohua S, Parker-Kerrigan B, Maheshwari A, Parra Cuentas ER, Navin NE, Heimberger AB, Lang FF, Iavarone A, Clise-Dwyer K, Wang L, Bhat KP. Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro Oncol. e-Pub 2024. PMID: 39126294.
- Park J, Wu J, Szkop KJ, Jeong J, Jovanovic P, Husmann D, Flores NM, Francis JW, Chen YC, Benitez AM, Zahn E, Song S, Ajani JA, Wang L, Singh K, Larsson O, Garcia BA, Topisirovic I, Gozani O, Mazur PK. SMYD5 methylation of rpL40 links ribosomal output to gastric cancer. Nature 632(8025):656-663, 2024. e-Pub 2024. PMID: 39048817.
- Cheng X, Dai E, Wu J, Flores NM, Chu Y, Wang R, Dang M, Xu Z, Han G, Liu Y, Chatterjee D, Hu C, Ying J, Du Y, Yang L, Guan X, Mo S, Cao X, Pei G, Jiang J, Lu X, Benitez AM, Waters RE, Pizzi MP, Shanbhag N, Fan Y, Peng F, Hanash SM, Calin G, Futreal A, Song S, Yee C, Mazur PK, Qin JJ, Ajani JA, Wang L. Atlas of metastatic gastric cancer links ferroptosis to disease progression and immunotherapy response. Gastroenterology. e-Pub 2024. PMID: 39097198.
- Jiang J, Liu Y, Qin J, Chen J, Wu J, Pizzi MP, Lazcano R, Yamashita K, Xu Z, Pei G, Cho KS, Chu Y, Sinjab A, Peng F, Yan X, Han G, Wang R, Dai E, Dai Y, Czerniak BA, Futreal A, Maitra A, Lazar A, Kadara H, Jazaeri AA, Cheng X, Ajani J, Gao J, Hu J, Wang L. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics. Nat Commun 15(1):7312, 2024. e-Pub 2024. PMID: 39181865.
- Siddiqui BA, Palaskas NL, Basu S, Dai Y, He Z, Yadav SS, Allison JP, Sheth RA, Tummala S, Buja M, Bhattacharjee MB, Iliescu C, Rawther-Karedath A, Deswal A, Wang L, Sharma P, Subudhi SK. Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositis. Cancer Immunol Res. e-Pub 2024. PMID: 38768394.
- Peshoff MM, Gupta P, Oberai S, Trivedi R, Katayama H, Chakrapani P, Dang M, Migliozzi S, Gumin J, Kadri DB, Lin JK, Milam NK, Maynard ME, Vaillant BD, Parker-Kerrigan B, Lang FF, Huse JT, Iavarone A, Wang L, Clise-Dwyer K, Bhat KP. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Neuro Oncol 26(5):826-839, 2024. e-Pub 2024. PMID: 38237157.
- Yamashita K, Sewastjanow-Silva M, Yoshimura K, Rogers JE, Rosa Vicentini E, Pool Pizzi M, Fan Y, Zou G, Li JJ, Blum Murphy M, Gan Q, Waters RE, Wang L, Ajani JA. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38610978.
- Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Çetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, Del Poggetto E, Loponte S, Liu J, Soeung M, Chen Z, Jiang S, Jiang H, Inoue A, Gao S, Deem A, Feng N, Ying H, Kim M, Giuliani V, Genovese G, Zhang J, Futreal A, Maitra A, Heffernan T, Wang L, Do KA, Gargiulo G, Draetta G, Carugo A, Lin R, Viale A. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv 10(11):eadd9342, 2024. e-Pub 2024. PMID: 38478609.
- Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature, 2024. e-Pub 2024. PMID: 38418883.
- Zhang D, Schroeder A, Yan H, Yang H, Hu J, Lee MYY, Cho KS, Susztak K, Xu GX, Feldman MD, Lee EB, Furth EE, Wang L, Li M. Inferring super-resolution tissue architecture by integrating spatial transcriptomics with histology. Nat Biotechnol. e-Pub 2024. PMID: 38168986.
- Li X, Henderson J, Gordon MJ, Sheikh I, Nastoupil LJ, Westin J, Flowers C, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green MR. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41(11):1835-1837, 2023. e-Pub 2023. PMID: 37738975.
- Fan Y, Song S, Li Y, Dhar SS, Jin J, Yoshimura K, Yao X, Wang R, Scott AW, Pizzi MP, Wu J, Ma L, Calin GA, Hanash S, Wang L, Curran M, Ajani JA. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases. Cancer Res 83(22):3726-3738, 2023. PMID: 37738407.
- Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming ovarian cancer care by targeting minimal residual disease. Med 4(11):755-760, 2023. PMID: 37951209.
- Dacic S, Cao X, Rabassedas NB, Sanchez-Espiridion B, Berezowska S, Han Y, Chung JH, Beasley MB, Dongmei L, Hwang D, Mino-Kenudson M, Minami Y, Papotti M, Rekhtman N, Roden AC, Thunnissen E, Tsao MS, Yatabe Y, Yoshida A, Wang L, Hartman DJ, Jerome JA, Kadara H, Chou TY, Wistuba I, IASLC Pathology Committeeds. Genomic staging of multifocal lung squamous cell carcinomas is independent of the comprehensive morphologic assessment. J Thorac Oncol. e-Pub 2023. PMID: 37717856.
- Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer 11(8), 2023. PMID: 37604642.
- Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. PMID: 37586321.
- Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, Li Y, Fan Y, Jin J, Dang M, Dai E, Pei G, Han G, Hao D, Li Y, Chatterjee D, Harada K, Pizzi MP, Scott AW, Tatlonghari G, Yan X, Xu Z, Hu C, Mo S, Shanbhag N, Lu Y, Sewastjanow-Silva M, Fouad Abdelhakeem AA, Peng G, Hanash SM, Calin GA, Yee C, Mazur P, Marsden AN, Futreal A, Wang Z, Cheng X, Ajani JA, #Wang L. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell, 2023. e-Pub 2023. PMID: 37419119.
- Fan H, Wang F, Zeng A, Murison A, Tomczak K, Hao D, Jelloul FZ, Wang B, Barrodia P, Liang S, Chen K, Wang L, Zhao Z, Rai K, Jain AK, Dick J, Daver N, Futreal A, Abbas HA. Single-cell chromatin accessibility profiling of acute myeloid leukemia reveals heterogeneous lineage composition upon therapy-resistance. Commun Biol 6(1):765, 2023. e-Pub 2023. PMID: 37479893.
- Li C, Zhang B, Schaafsma E, Reuben A, Wang L, Turk MJ, Zhang J, Cheng C. TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs. Cell Rep Med 4(7):101121, 2023. PMID: 37467716.
- Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. e-Pub 2023. PMID: 37327788.
- Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nat Rev Clin Oncol. e-Pub 2023. PMID: 37264184.
- Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, #Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med, 2023. e-Pub 2023. PMID: 37248301.
- Zhao S, Wang R, Song S, Hao D, Han G, Song X, Zhang J, Pizzi MP, Shanbhag N, Futreal A, Badgwell B, Harada K, Calin G, Vykoukal J, Yu CY, Katayama H, Hanash SM, Wang L, Ajani JA. Proteogenomic landscape of gastric adenocarcinoma peritoneal metastases. iScience 26(6):106913, 2023. e-Pub 2023. PMID: 37305699.
- Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer. e-Pub 2023. PMID: 37365326.
- Jin J, Huo L, Fan Y, Wang R, Scott AW, Pizzi MP, Yao X, Shao S, Ma L, Da Silva MS, Yamashita K, Yoshimura K, Zhang B, Wu J, Wang L, Song S, Ajani JA. A new intronic quantitative PCR method led to the discovery of transformation from human ascites to murine malignancy in a mouse model. Front Oncol 13:1062424, 2023. e-Pub 2023. PMID: 36865791.
- Dang M, Wang R, Lee HC, Patel KK, Becnel MR, Han G, Thomas SK, Hao D, Chu Y, Weber DM, Lin P, Lutter-Berka Z, Berrios Nolasco DA, Huang M, Bansal H, Song X, Zhang J, Futreal A, Moreno Rueda LY, Symer DE, Green MR, Rojas Hernandez CM, Kroll M, Afshar-Khargan V, Ndacayisaba LJ, Kuhn P, Neelapu SS, Orlowski RZ, #Wang L (Co-senior & corresponding), Manasanch EE. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4, 2023. e-Pub 2023. PMID: 37311413.
- Hu J, Coleman K, Zhang D, Lee EB, Kadara H, #Wang L (Co-senior & corresponding), Li M. Deciphering tumor ecosystems at super resolution from spatial transcriptomics with TESLA. Cell Syst 14(5):404-417.e4, 2023. e-Pub 2023. PMID: 37164011.
- Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, #Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov, 2022. e-Pub 2022. PMID: 36098652.
- Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, #Wang L (Co-senior & corresponding), Wang M. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21(1):185, 2022. e-Pub 2022. PMID: 36163179.
- Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. Blood 140(5):504-515, 2022. PMID: 35512184.
- Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut, 2022. e-Pub 2022. PMID: 36002248.
- Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, #Wang L (Co-senior & corresponding), Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov, 2022. e-Pub 2022. PMID: 35687817.
- Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature 606(7915):797-803, 2022. e-Pub 2022. PMID: 35705814.
- Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, #Wang L (Co-senior & corresponding), Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
- Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, #Wang L (Co-senior & corresponding), Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
- Dong X, Song S, Li Y, Fan Y, Wang L, Wang R, Huo L, Scott A, Xu Y, Pizzi MP, Ma L, Wang Y, Jin J, Zhao W, Yao X, Johnson RL, Wang L, Wang Z, Peng G, Ajani JA. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency. Gut, 2022. e-Pub 2021. PMID: 33785559.
- Fedoriw A, Shi L, O'Brien S, Smitheman KN, Wang Y, Hou J, Sherk C, Rajapurkar S, Laraio J, Williams LJ, Xu C, Han G, Feng Q, Bedford MT, Wang L, Barbash O, Kruger RG, Hwu P, Mohammad HP, Peng W. Inhibiting Type I arginine methyltransferase activity promotes the T cell mediated antitumor immune response. Cancer Immunol Res, 2022. e-Pub 2022. PMID: 35181787.
- Wang M, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, OK CY, Kanagal-Shamanna R, Hill HA, Yao Y, Liu Y, Hagemeister FB, Westin J, Fowler N, Samaniego F, Steiner R, Chen W, Oriabure O, Moghrabi OB, Navsaria L, Che Y, Li Y, Avellaneda M, Badillo M, Feng L, Nogueras Gonzalez G, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang S, Yin CC, Li S, Patel KM, Vega F, Medeiros LJ, Flowers CR, *Wang L. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, 2022. e-Pub 2022.
- Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, Wang L, Lin Y, Wang Z, Jaffray D, Hazle JD, Macapinlac HA, Wu J, Lu Y. Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma. Clin Nucl Med, 2022. e-Pub 2022. PMID: 35020640.
- Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
- Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, #Wang L (Co-senior), Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol, 2021. e-Pub 2021. PMID: 34789422.
- Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, *Wang L (Co-senior), Wang ML. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol:JCO2101797, 2021. e-Pub 2021. PMID: 34797699.
- Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA.. Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers 13(21):5301, 2021. e-Pub 2021.
- Abbas HA, Hao D, Tomczak K, Barrodia P, Im JS, Reville PK, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird HC, Mathews JT, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Solis LM, Parra ER, Lu W, Tamegnon A, Garcia-Manero G, Green MR, Sharma P, Allison JP, Kornblau SM, Rai K, #Wang L (Co-senior & corresponding), Daver N, Futreal A. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun 12(1):6071, 2021. e-Pub 2021. PMID: 34663807.
- Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, #Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
- Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373(6561):eabj0486, 2021. e-Pub 2021. PMID: 34529467.
- Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, Scott AW, Pizzi MP, Wang Y, Fan Y, Harada K, Jin J, Ma L, Yao X, Shanbhag ND, Gan Q, Roy-Chowdhuri S, Badgwell BD, Wang Z, Wang L, Ajani JA. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. J Exp Clin Cancer Res 40(1):207, 2021. e-Pub 2021. PMID: 34162421.
- Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan P, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021. e-Pub 2021. PMID: 34041526.
- Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, #Wang L (Co-senior & corresponding), Wang M. Longitudinal Single-Cell Profiling Reveals Molecular Heterogeneity and Tumor-Immune Evolution in Refractory Mantle Cell Lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
- Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, #Wang L (Co-senior & corresponding), Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov, 2021. e-Pub 2021. PMID: 33972311.
- Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, #Wang L (Co-senior & corresponding), Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33809063.
- Bailey CP, Wang R, Figueroa M, Zhang S, Wang, L, Chandra J.. Computational immune infiltration analysis of pediatric high-grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location. Computational and Systems Oncology, 2021. e-Pub 2021.
- Kim ST, Sheshadri A, Shannon V, Kontoyiannis DP, Kantarjian H, Garcia-Manero G, Ravandi F, Im JS, Boddu P, Bashoura L, Balachandran DD, Evans SE, Faiz S, Ruiz Vazquez W, Divenko M, Mathur R, Tippen SP, Gumbs C, Neelapu SS, Naing A, Wang L, Diab A, Futreal A, Nurieva R, Daver N. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol 11:590494, 2021. e-Pub 2021. PMID: 33552049.
- Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, Zhao M, Tatlonghari G, Zhang S, Hao D, Lu Y, Zhao S, Badgwell BD, Blum Murphy M, Shanbhag N, Estrella JS, Roy-Chowdhuri S, Abdelhakeem AAF, Wang Y, Peng G, Hanash S, Calin GA, Song X, Chu Y, Zhang J, Li M, Chen K, Lazar AJ, Futreal A, Song S, Ajani JA, #Wang L. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med, 2021. e-Pub 2021. PMID: 33398161.
- Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol, 2021. e-Pub 2021. PMID: 33491779.
- Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JJ, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):687, 2021. e-Pub 2021. PMID: 33514726.
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, Dai E, Dang M, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Sun R, Hagemeister F, Fayad L, Samaniego F, Lee HC, Nastoupil LJ, Fowler N, Eric Davis R, Westin J, Neelapu SS, #Wang L (Co-senior & corresponding), Green MR. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26(12):1878-1887, 2020. e-Pub 2020. PMID: 33020644.
- Hao D, He S, Harada K, Pizzi MP, Lu Y, Guan P, Chen L, Wang R, Zhang S, Sewastjanow-Silva M, Abdelhakeem A, Shanbhag N, Bhutani M, Han G, Lee JH, Zhao S, Weston B, Blum Murphy M, Waters R, Estrella JS, Roy-Chowdhuri S, Gan Q, Lee JS, Peng G, Hanash SM, Calin GA, Song X, Zhang J, Song S, #Wang L (Co-senior & corresponding), Ajani JA. Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut, 2020. e-Pub 2020. PMID: 33334899.
- Farah M, Reuben A, Spassova I, Yang RK, Kubat L, Nagarajan P, Ning J, Li W, Aung PP, Curry JL, Torres-Cabala CA, Hudgens CW, Ugurel S, Schadendorf D, Gumbs C, Little LD, Futreal A, Wistuba II, Prieto VG, Wang L, Wong MK, Wargo JA, Becker JC, Tetzlaff MT. T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. J Invest Dermatol 140(11):2146-2156.e4, 2020. e-Pub 2020. PMID: 32304704.
- Sinjab A, Han G, Wang L, Kadara H. Field Carcinogenesis in Cancer Evolution: What the Cell Is Going On?. Cancer Res 80(22):4888-4891, 2020. e-Pub 2020. PMID: 33023945.
- Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Piñeyro D, Castro de Moura M, Esteller M, Shen H, Zenklusen JC, Tarnuzzer R, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn EC, Little RF, White J, Malik S, Harris L, Weil C, Chen AP, Karlovich C, Rodgers B, Shankar L, Jacobs P, Nolan T, Hu J, Muzny DM, Doddapaneni H, Korchina V, Gastier-Foster J, Bowen J, Leraas K, Edmondson EF, Doroshow JH, Conley BA, Ivy SP, Staudt LM. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell, 2020. e-Pub 2020. PMID: 33217343.
- Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, Singh AK, Raman AT, Terranova C, Sarkar S, Orouji E, Amin SB, Sharma S, Williams M, Samant NS, Dhamdhere M, Zheng N, Shah T, Shah A, Axelrad JB, Anvar NE, Lin YH, Jiang S, Chang EQ, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep 33(3):108293, 2020. PMID: 33086062.
- Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporiciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target. J Thorac Oncol, 2020. e-Pub 2020. PMID: 33388477.
- Li Y, Song S, Pizzi MP, Han G, Scott AW, Jin J, Xu Y, Wang Y, Huo L, Ma L, Vellano C, Luo X, MacLeod R, Wang L, Wang Z, Ajani JA. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33076512.
- Bailey CP, Figueroa M, Gangadharan A, Yang Y, Romero MM, Kennis BA, Yadavilli S, Henry V, Collier T, Monje M, Lee DA, Wang L, Nazarian J, Gopalakrishnan V, Zaky W, Becher OJ, Chandra J. Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG). Neuro Oncol 22(9):1302-1314, 2020. e-Pub 2020. PMID: 32166329.
- Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AM. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med 12(554), 2020. PMID: 32727914.
- Li Y, Yang S, Sadaoui NC, Hu W, Dasari SK, Mangala LS, Sun Y, Zhao S, Wang L, Liu Y, Ramondetta LM, Li K, Lu C, Kang Y, Cole SW, Lutgendorf SK, Sood AK. Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. iScience 23(7):101289, 2020. e-Pub 2020. PMID: 32623336.
- Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, #Wang L (Co-senior & corresponding), Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
- Lu Y, Wang L, Ajani JA. Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. Clin Nucl Med 45(4):334-335, 2020. e-Pub 2020. PMID: 31977493.
- Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of A National Cancer Institute Pilot Study. J Natl Cancer Inst, 2020. e-Pub 2020. PMID: 32339229.
- Ajani JA, Xu Y, Huo L, Wang R, Li Y, Wang Y, Pizzi MP, Scott A, Harada K, Ma L, Yao X, Jin J, Zhao W, Dong X, Badgwell BD, Shanbhag N, Tatlonghari G, Estrella JS, Roy-Chowdhuri S, Kobayashi M, Vykoukal JV, Hanash SM, Calin GA, Peng G, Lee JS, Johnson RL, Wang Z, Wang L, Song S. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. Gut, 2020. e-Pub 2020. PMID: 32345613.
- Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. PMID: 32188704.
- Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, *Wang L(Co-senior), Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. PMID: 32191807.
- ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578(7793):82-93, 2020. e-Pub 2020. PMID: 32025007.
- Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, *Wang L(Co-senior), Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
- Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 18(1):141, 2019. e-Pub 2019. PMID: 31601234.
- Manasanch EE, Han G, Mathur R, Qing Y, Zhang Z, Lee H, Weber DM, Amini B, Berkova Z, Eterovic K, Zhang S, Zhang J, Song X, Mao X, Morgan M, Feng L, Baladandayuthapani V, Futreal A, *Wang L(Co-senior), Neelapu SS, Orlowski RZ. A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Adv 3(15):2400-2408, 2019. PMID: 31405950.
- Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, #Wang L (Co-senior & corresponding), Ajani JA. Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2019. e-Pub 2019. PMID: 31171626.
- Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA. Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunol Res 7(6):1025-1035, 2019. e-Pub 2019. PMID: 31043414.
- Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, Bell T, Zhang H, Han G, Lorence E, Badillo M, Zhou S, Sun Y, Di Francesco ME, Feng N, Haun R, Lan R, Mackintosh SG, Mao X, Song X, Zhang J, Pham LV, Lorenzi PL, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, #Wang L (Co-senior & corresponding), Wang M. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med 11(491), 2019. PMID: 31068440.
- Liu J, Huang Z, Yang L, Wang X, Wang S, Li C, Liu Y, Cheng Y, Wang B, Sang X, He X, Wang C, Liu T, Liu C, Jin L, Liu C, Zhang X, Wang L, Wang Z. Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma. Theranostics 9(16):4764-4778, 2019. e-Pub 2019. PMID: 31367256.
- Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pool Pizzi M, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA. YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer. Clin Cancer Res. e-Pub 2018. PMID: 30563933.
- Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, *Wang L (Co-senior), Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. e-Pub 2018. PMID: 30175400.
- Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
- Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, MC3 Working Group, Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 174(4):1034-1035, 2018. PMID: 30096302.
- Shen H, Shih J, Hollern DP, *Wang L (Co-first), Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, ZenKlusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM, Cancer Genome Atlas Research Network, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA. Integrated molecular characterization of testicular germ cell tumors. Cell Rep 23(11):3392-3406, 2018. PMID: 29898407.
- Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. Oncoimmunology 7(8):e1467856, 2018. e-Pub 2018. PMID: 30221071.
- Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173(2):291-304.e6, 2018. PMID: 29625048.
- Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321-337.e10, 2018. PMID: 29625050.
- Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. Immunity 48(4):812-830.e14, 2018. e-Pub 2018. PMID: 29628290.
- Knijnenburg TA, *Wang L (Co-first), Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Cancer Genome Atlas Research Network, Monnat RJ, Xiao Y, Wang C.. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep 23(1):239-254.e6, 2018. PMID: 29617664.
- Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Cancer Genome Atlas Research Network, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep 23(1):172-180.e3, 2018. PMID: 29617658.
- Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research Network, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Rep 23(1):181-193.e7, 2018. PMID: 29617659.
- Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cancer Genome Atlas Research Network, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell 33(4):676-689.e3, 2018. e-Pub 2018. PMID: 29622463.
- TCGA-HCC group including *Wang L (as one of the major contributing authors). Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169(7):1327-1341.e23, 2017. PMID: 28622513.
- Goschzik T, Gessi M, Dreschmann V, Gebhardt U, Wang L, Yamaguchi S, Wheeler DA, Lauriola L, Lau CC, Müller HL, Pietsch T. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma. J Neuropathol Exp Neurol. e-Pub 2017. PMID: 28069929.
- Lanikova L, Babosova O, Swierczek S, Wang L, Wheeler DA, Divoky V, Korinek V, Prchal JT. Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera. Blood 128(18):2266-2270, 2016. e-Pub 2016. PMID: 27647865.
- Eckstein OS, *Wang L (Co-first), Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE. Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44(8):740-4, 2016. e-Pub 2016. PMID: 27208809.
- Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, Xi L, Meng Q, Langridge T, Drummond J, Donehower LA, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Duvic M. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 47(12):1426-34, 2015. e-Pub 2015. PMID: 26551670.
- Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP, Covington KR, Trevino L, Dewal N, Muzny DM, Doddapaneni H, Hu J, Wang L, Lupo PJ, Hicks MJ, Bonilla DL, Dwyer KC, Berres ML, Poulikakos PI, Merad M, McClain KL, Wheeler DA, Allen CE, Parsons DW. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007-15, 2014. e-Pub 2014. PMID: 25202140.
- Arai E, Sakamoto H, Ichikawa H, Totsuka H, Chiku S, Gotoh M, Mori T, Nakatani T, Ohnami S, Nakagawa T, Fujimoto H, Wang L, Aburatani H, Yoshida T, Kanai Y. Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer 135(6):1330-42, 2014. e-Pub 2014. PMID: 24504440.
- Wang L, Yamaguchi S, Burstein MD, Terashima K, Chang K, Ng HK, Nakamura H, He Z, Doddapaneni H, Lewis L, Wang M, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adekunle A, Sun J, Qiao Y, Marth G, Muzny DM, Gibbs RA, Leal SM, Wheeler DA, Lau CC. Novel somatic and germline mutations in intracranial germ cell tumours. Nature 511(7508):241-5, 2014. e-Pub 2014. PMID: 24896186.
- Wang L, Swierczek SI, Lanikova L, Kim SJ, Hickman K, Walker K, Wang K, Drummond J, Doddapaneni H, Reid JG, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT. The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. Leukemia 28(4):938-41, 2014. e-Pub 2014. PMID: 24463469.
- Wang L, Swierczek SI, Drummond J, Hickman K, Kim SJ, Walker K, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia 28(4):935-8, 2014. e-Pub 2014. PMID: 24413320.
- Ikeda Y, Oda K, Nakagawa S, Murayama-Hosokawa S, Yamamoto S, Ishikawa S, Wang L, Takazawa Y, Maeda D, Wada-Hiraike O, Kawana K, Fukayama M, Aburatani H, Yano T, Kozuma S, Taketani Y. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. Int J Gynecol Cancer 22(5):725-31, 2012. PMID: 22635024.
- Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Saiura A, Hirono S, Yamaue H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Ueda H, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 22(2):208-19, 2012. e-Pub 2011. PMID: 22156295.
- Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, Tsutsumi S, Sonoda K, Totsuka H, Shirakihara T, Sakamoto H, Wang L, Ojima H, Shimada K, Kosuge T, Okusaka T, Kato K, Kusuda J, Yoshida T, Aburatani H, Shibata T. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43(5):464-9, 2011. e-Pub 2011. PMID: 21499249.
Invited Articles
- Gulati GS, D'Silva JP, Liu Y, Wang L, Newman AM. Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics. Nat Rev Mol Cell Biol. e-Pub 2024. PMID: 39169166.
- Wang L, Li M, Hwang TH. The 3D Revolution in Cancer Discovery. Cancer Discov 14(4):625-629, 2024. PMID: 38571426.
- Theis FJ, Dar D, Vento-Tormo R, Vickovic S, Wang L, Kagohara LT, Rendeiro AF, Joyce JA. What do you most hope spatial molecular profiling will help us understand? Part 1. Cell Syst 14(6):423-427, 2023. e-Pub 2023. PMID: 37348459.
- Wang L. Stress response in tumor-infiltrating T cells is linked to immunotherapy resistance. Nat Med, 2023. e-Pub 2023. PMID: 37253923.
- Wang L. Developmental Deconvolution Suggests New Tumor Biology and a Tool for Predicting Cancer Origin. Cancer Discov 12(11):2498-2500, 2022. e-Pub 2022. PMID: 36321308.
- Anderson AC, Yanai I, Yates LR, *Wang L (equal contribution), Swarbrick A, Sorger P, Santagata S, Fridman WH, Gao Q, Jerby L, Izar B, Shang L, Zhou X. Spatial transcriptomics. Cancer Cell 40(9):895-900, 2022. PMID: 36099884.
- Wang L, Ajani JA. Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. Clin Cancer Res. e-Pub 2019. PMID: 31527165.
- Wang L, Wheeler DA, Prchal JT.. Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol 44(8):644-52, 2016. e-Pub 2015. PMID: 26646991.
- Wang L & Wheeler DA.. Genomic sequencing for cancer diagnosis and therapy. Annu Rev Med 65:33-48, 2014. e-Pub 2013. PMID: 24274147.
- Wheeler DA, #Wang L. From human genome to cancer genome: the first decade. Genome Res 23(7):1054-62, 2013. PMID: 23817046.
- Aburatani H, #Wang L. Integrated genomic analysis of pancreatic ductal carcinoma. Experimental Medicine 30:33-38, 2012.
Other Articles
- Luigi Perelli, Li Zhang, Sarah Mangiameli, Andrew James Charles Russell, Francesca Giannese, Fuduan Peng, Federica Carbone, Courtney Le, Hania Khan, Francesca Citron, Melinda Soeung, Truong Lam, Sebastian Lundgren, Cihui Zhu, Desiree Catania, Ningping Feng, Enrico Gurreri, Alessandro Sgambato, Giampaolo Tortora, Giulio Draetta, Giovanni Tonon, Andrew Futreal, Virginia Giuliani, Alessandro Carugo, Andrea Viale, Timothy Heffernan, Linghua Wang, Davide Cittaro, Fei Chen, Giannicola Genovese Evolutionary fingerprints of EMT in pancreatic cancers. BioRxiv 2023.09.18.558231, 2023.
- Patrick K Reville, Irtiza N Sheikh, Ahyun Choi, Enyu Dai, Jared Henderson, Xubin Li, Estela Rojas, Cuong Le, Chizitara Okwuchi, Mikielia Devonish, Roberto Carrio, Nathan Pate, Katie Malley, Dinesh Bangari, Julie-Ann Givigan, Chaomei Shi, Bing Liu, Tony Byers, Jason Westin, Sairah Ahmed, Nathan Fowler, Luis Fayad, Hun Ju Lee, Loretta Nastoupil, Ingrid Sassoon, Margot Cucchetti, Rui Wang, Maria Agarwal, Giovanni Abbadessa, Robin Meng, Elamaran Meibalan, Laura Powers, James Cao, Xiaoyou Ying, Kelly Balko, Qunyan Yu, Jing Jiao, Virna Cortez-Retamozo, Sukhvinder Sidhu, Donald Shaffer, Sattva Neelapu, Linghua Wang, Xiangming Li, Michael Green CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin. BioRxiv 2023.08.28.555127, 2023.
- Pravesh Gupta, Minghao Dang, Shivangi Oberai, Mekenzie Peshoff, Nancy Milam, Aml Ahmed, Krishna Bojja, Tuan M. Tran, Kathryn Cox, Huma Shehwana, Carlos Kamiya-Matsuoka, Jianzhuo Li, Joy Gumin, Alicia Goldman, Sameer A. Seth, Atul Maheshwari, Frederick F. Lang, Nicholas E. Navin, Amy B. Heimberger, Karen Clise-Dwyer, #Linghua Wang (Co-senior & corresponding), Krishna P. Bhat Immune landscape of isocitrate dehydrogenase stratified human gliomas. bioRxiv, 2022.
- Xiuning Le, Minghao Dang, VenkateshL. Hegde, Bo Jiang, Ravaen Slay, Weihong Xiao, Keiko Akagi, Joseph Fresquez, Kathrina L. Marcelo, Qianyun Luo, Pragya Sinha, Ananta V. Yanamandra, JoeDan Dunn, Diana Bell, Michelle Williams, Edwin Parra, Ryan Goepfert, Stephen H. Lai, Neil Gross, Amit Agrawal, Alexandre Reuben, Jeffrey Myers, Michael A. Curran, K. Jagannadha Sastry, #Linghua Wang (Co-senior & corresponding), Maura L. Gillison TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas. medRxiv, 2021.
- Guangchun Han, Qing Deng, Enyu Dai, Minghao Dang, John Ma, Haopeng Yang, Olga Kudryashova, Mark Meerson, Sergey Isaev, Nikita Kotlov, Krystle Nomie, Alexander Bagaev, Simrit Parmar, Fredrick Hagemeister, Sairah Ahmed, Swami Iyer, Filepe Samaniego, Raphael Steiner, Luis Fayad, Hun Lee, Nathan Fowler, Francisco Vega, Christopher R. Flowers, Paolo Strati, Jason R. Westin, Sattva S. Neelapu, Loretta J. Nastoupil, #Linghua Wang (Co-senior & corresponding), Michael R. Green. Immune microenvironment subtypes and association with tumor cell mutations and antigen expression in follicular lymphoma. bioRxiv, 2021.
- Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, Wang M, Ajani J, Futreal A, #Wang L iTALK: an R Package to Characterize and Illustrate Intercellular Communication. BioRxiv, 2020.
Grant & Contract Support
Title: | Start-up fund for Tenure-Track Assistant Professor |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | Principal Investigator |
Title: | High-Risk Multiple Myeloma Moon Shot Program |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | Co-Program Leader |
Title: | Targeting Tim-3 as a Novel Therapeutic Strategy for Advanced Gastric Cancer with Peritoneal Metastases |
Funding Source: | Andrew Sabin Family Foundation |
Role: | Principal Investigator |
Title: | Dissecting the Multicellular Ecosystem of Metastatic Gastric Adenocarcinoma by Longitudinal Single Cell Sequencing of Malignant Ascites Cells and PBMCs with Primary and Normal Gastric Tissue as control |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | Principal Investigator |
Title: | Ovarian SPORE CEP Award |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Lung SPORE CEP Award |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Predicting Response and Improving Efficacy of CAR T-cell Therapy in DLBCL |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Principal Investigator |
Title: | Contribution of tumor heterogeneity in eliciting response to the immune system |
Funding Source: | The V Foundation |
Role: | Co-Investigator |
Title: | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Analysis of the genetic landscape in the evolution of oligometastatic prostate cancer through peripheral bioanalytes |
Funding Source: | Department of Defense (DOD) |
Role: | Collaborator |
Title: | Identifying the determinants of clinical responses to PARP inhibitors in ovarian cancer immunotherapy |
Funding Source: | Department of Defense (DOD) |
Role: | Co-Investigator |
Title: | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance |
Funding Source: | NIH/NCI |
Role: | Principal Investigator |
Title: | Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development |
Funding Source: | NIH/NCI |
Role: | Co-Principal Investigator |
Title: | Evolution of small-cell lung cancer from the normal airway |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Investigator |
Title: | Single-Cell Decoding of Spatiotemporal and Ecological Evolution in Early-Stage KRAS-Mutant Lung Cancer |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-Principal Investigator |
Title: | Translating Novel Discoveries in Gastric Adenocarcinoma Biology into Therapeutic Advances |
Funding Source: | Department of Defense (DOD) |
Role: | Co-Investigator |
Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer |
Funding Source: | NIH/NCI |
Role: | Co-Shared Resource Director |
Title: | Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Development of novel tumor microenvironment targeted therapy in inflammatory breast cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Targeting Ovarian Cancer Minimal Residual Disease (MRD) Using Immune and DNA Repair Directed Therapies |
Funding Source: | Break Through Cancer |
Role: | Co-Principal Investigator |
Title: | Conquering KRAS in Pancreatic Cancer |
Funding Source: | Break Through Cancer |
Role: | Co-Principal Investigator |
Title: | “Understanding and intercepting ovarian carcinogenesis” The BTC Minimal Original Disease (MOD) Ovarian Cancer Team |
Funding Source: | Break Through Cancer |
Role: | Co-Investigator |
Title: | PASSCODE (Pancreatic Adenocarcinoma Stromal Reprograming ConSortium COordination, Data Management and Education) |
Funding Source: | NIH/NCI |
Role: | Lead of the Data Analysis and Data Visualization Unit |
Title: | Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer |
Funding Source: | NIH/NCI |
Role: | Co-Investigator |
Title: | Data Science Hub |
Funding Source: | Break Through Cancer |
Role: | Co-Principal Investigator |
Title: | Program for T Cell-based Therapy (ProTCT) |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | Lead of TCR Correlatives Focus Area |
Title: | Spatial Charting the Development of Hereditary Diffuse Gastric Cancer in CDH1 Mutation Carriers |
Funding Source: | The University of Texas MD Anderson Cancer Center |
Role: | Principal Investigator |